Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CEL-SCI Corp

CVM ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.54

▲ +3.36%

Market Cap $26.91M · Vol 18.87K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$26.91M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

65.79

Momentum

Beta

0.65

vs Market

52W High

$13.27

88.39% below

52W Low

$0.89

73.03% above

Volume

18.87K

Avg 20.05K

P/B

4.62

Price-to-book

ROE

N/A

Return on equity

Free Float

93.69%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, CEL-SCI Corp (CVM) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CVM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.47%

+33.91%

+18.46%

-68.57%

YTD

-70.72%

-81.08%

-96.11%

-99.43%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-25,411,060.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-92.16% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.62
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	17.48M

Technical Indicators

50-Day SMA	$1.24
200-Day SMA	$3.74
RSI (14)	65.79
Beta	0.65
52-Week High	$13.27
52-Week Low	$0.89

Volume Today	18.87K
Avg Daily Volume (30D)	20.05K
Relative Volume	0.94x
Volatility (10D)	109.05
Volatility (30D)	97.24
Free Float	93.69%

Analyst Consensus

BUY

Current Price $1.54

Mean Target $10.00

52W Low$0.89 52W High$13.27

Current

Target

$0.89 $13.27

Current Analyst target

+549.35% upside potential · 0 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001SBRBG1

ISINUS1508377066

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).